Molecular Therapy
Volume 25, Issue 1, 4 January 2017, Pages 165-180
Journal home page for Molecular Therapy

Original Article
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice

https://doi.org/10.1016/j.ymthe.2016.08.001Get rights and content
Under a Creative Commons license
open archive

Diabetic nephropathy is the main cause of end-stage renal disease. MicroRNAs are powerful regulators of the genome, and global expression profiling revealed miR-21 to be among the most highly regulated microRNAs in kidneys of mice with diabetic nephropathy. In kidney biopsies of diabetic patients, miR-21 correlated with tubulointerstitial injury. In situ PCR analysis showed a specific enrichment of miR-21 in glomerular cells. We identified cell division cycle 25a (Cdc25a) and cyclin-dependent kinase 6 (Cdk6) as novel miR-21 targets in mesangial cells. miR-21-mediated repression of Cdc25a and Cdk6 resulted in impaired cell cycle progression and subsequent mesangial cell hypertrophy. miR-21 increased podocyte motility by regulating phosphatase and tensin homolog (Pten). miR-21 antagonism in vitro and in vivo in streptozotocin-induced diabetic mice decreased mesangial expansion, interstitial fibrosis, macrophage infiltration, podocyte loss, albuminuria, and fibrotic- and inflammatory gene expression. In conclusion, miR-21 antagonism rescued various functional and structural parameters in mice with diabetic nephropathy and, thus, might be a viable option in the treatment of patients with diabetic kidney disease.

Keywords

diabetic nephropathy
TGF-β
microRNA
miR-21
cell-cycle regulators
mesangial hypertrophy
podocyte motility

Cited by (0)

8

These authors contributed equally to this work.